Rosuvastatin calcium 20 mg
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest that rosuvastatin calcium 20 mg is bioequivalent across different populations, effective in treating hyperlipidemia and coronary heart disease, and exhibits consistent pharmacokinetics with good safety and stability.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Rosuvastatin Calcium 20 mg: Pharmacokinetics, Bioequivalence, and Clinical Efficacy
Pharmacokinetics of Rosuvastatin Calcium 20 mg
Rosuvastatin calcium, a potent statin used for lowering cholesterol, exhibits significant pharmacokinetic variability among different populations. Studies have shown that the pharmacokinetic parameters such as peak plasma concentration (Cmax) and area under the curve (AUC) can vary significantly based on genetic and racial differences . For instance, a study on healthy Chinese volunteers demonstrated that the systemic exposure (AUC) to rosuvastatin is approximately two-fold higher in Asian subjects compared to Caucasians. This variability is attributed to genetic polymorphisms in transport proteins and enzymes involved in drug metabolism, such as ABCB1 and ABCG2.
Bioequivalence of Rosuvastatin Calcium 20 mg
Bioequivalence studies are crucial for ensuring that generic formulations of rosuvastatin calcium are as effective and safe as the branded versions. A study conducted among Mediterranean Arabs showed that the generic and branded 20 mg rosuvastatin tablets were bioequivalent, with no significant differences in the main pharmacokinetic parameters (Cmax and AUC). Similar findings were observed in a study comparing domestic and imported rosuvastatin tablets in healthy volunteers, which also demonstrated bioequivalence. These studies confirm that generic formulations can be used interchangeably with branded products, ensuring consistent therapeutic outcomes.
Clinical Efficacy and Safety of Rosuvastatin Calcium 20 mg
Rosuvastatin calcium at a 20 mg dose has been shown to be highly effective in lowering cholesterol levels and improving cardiovascular outcomes. In elderly patients with coronary heart disease (CHD) and hyperlipidemia, a 20 mg dose significantly reduced total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) levels more effectively than lower doses . Additionally, the 20 mg dose was found to be superior in reducing high-sensitive C-reactive protein (hs-CRP) levels, an inflammatory marker associated with cardiovascular risk.
Furthermore, in patients with cerebral infarction, a high dose of 20 mg rosuvastatin calcium was more effective in reducing the volume of carotid plaques and lipid cores compared to a 10 mg dose, indicating its potential in plaque stabilization and atherosclerosis management. The safety profile of rosuvastatin calcium 20 mg was comparable to lower doses, with no significant increase in adverse events .
Stabilization and Formulation of Rosuvastatin Calcium Tablets
The stability of rosuvastatin calcium is a critical factor in its formulation. Research has shown that using tribasic calcium phosphate as an excipient can stabilize rosuvastatin in tablet formulations, ensuring reliable and consistent drug release. This stabilization is essential for maintaining the drug's efficacy and safety during storage and use.
Conclusion
Rosuvastatin calcium 20 mg is a highly effective and safe option for managing hyperlipidemia and reducing cardiovascular risk. Its pharmacokinetic profile varies among different populations, necessitating consideration of genetic factors in dosing. Bioequivalence studies confirm that generic formulations are as effective as branded versions. The 20 mg dose offers superior lipid-lowering effects and plaque stabilization, making it a valuable option in clinical practice.
Sources and full results
Most relevant research papers on this topic
